Results 161 to 170 of about 4,177,143 (225)
Some of the next articles are maybe not open access.
The Impact of Regulatory Reforms in China on Drug Lag: The Role of Clinical Development Strategies
Clinical pharmacology and therapyIn recent years, there has been significant focus on China's new drug lag, but relevant research is limited. This study explores the reasons for drug lag by assessing the impact of reforms in China's drug review system, particularly focusing on the ...
Yue Han +5 more
semanticscholar +1 more source
JAMA: The Journal of the American Medical Association, 1978
IN RECENT testimony to a Senate subcommittee seeking ways to improve the drug regulation process in the United States, I insisted that an essential element in the updating of our drug laws must be the enhanced ability to expedite the approval of important therapeutic advances.
openaire +2 more sources
IN RECENT testimony to a Senate subcommittee seeking ways to improve the drug regulation process in the United States, I insisted that an essential element in the updating of our drug laws must be the enhanced ability to expedite the approval of important therapeutic advances.
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1975
To the Editor.— A TRENDS IN THERAPY article (231:635, 1975) implied that trimethoprim-sulfamethoxazole (Bactrim, Septra) is a new introduction to the US medical profession. It was launched here in Britain in 1968, and seven years of usage have confirmed its invaluable and by-and-large danger-free contribution to medicine.
openaire +1 more source
To the Editor.— A TRENDS IN THERAPY article (231:635, 1975) implied that trimethoprim-sulfamethoxazole (Bactrim, Septra) is a new introduction to the US medical profession. It was launched here in Britain in 1968, and seven years of usage have confirmed its invaluable and by-and-large danger-free contribution to medicine.
openaire +1 more source
European disclosure of drug company payments lags behind USA
Drug and Therapeutics Bulletin, 2022Abstract Overview of: Ozieranski P, Martinon L, Jachiet PA, et al. Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review. BMJ Open. 2021;11:e053138.
openaire +2 more sources
Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US
Therapeutic Innovation and Regulatory Science, 2023Akio Maki, M. Narukawa
semanticscholar +1 more source
The drug lag issue: a 20-year review of China
Investigational new drugs, 2021Xiaoyu Li, Yue Yang
semanticscholar +1 more source
Just a Little Bit More About Drug Lag
JAMA: The Journal of the American Medical Association, 1978IN AN article in the May 12, 1978, issue of JAMA , William Wardell, MD, PhD, delivered a lengthy rebuttal to an earlier article of mine on the so-called "drug lag." Because both sides of the argument have been stated in fairly extended form, I am satisfied to leave to the fair-minded reader the judgment of those issues in which we genuinely differ.
openaire +2 more sources
Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017
Therapeutic Innovation and Regulatory Science, 2020Sang-Won Lee +6 more
semanticscholar +1 more source
Therapeutic Innovation and Regulatory Science, 2022
Atsushi Noguchi, H. Hanaoka, Y. Uyama
semanticscholar +1 more source
Atsushi Noguchi, H. Hanaoka, Y. Uyama
semanticscholar +1 more source
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly